Blue Trust Inc. Grows Stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Blue Trust Inc. boosted its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 140.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 2,422 shares of the biopharmaceutical company’s stock after purchasing an additional 1,414 shares during the quarter. Blue Trust Inc.’s holdings in Xenon Pharmaceuticals were worth $95,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals during the 4th quarter worth $101,000. nVerses Capital LLC purchased a new position in Xenon Pharmaceuticals during the 3rd quarter valued at about $102,000. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 487 shares in the last quarter. Vestcor Inc purchased a new stake in shares of Xenon Pharmaceuticals in the third quarter valued at about $327,000. Finally, Elmwood Wealth Management Inc. grew its position in shares of Xenon Pharmaceuticals by 44.7% in the fourth quarter. Elmwood Wealth Management Inc. now owns 11,007 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 3,400 shares during the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on XENE shares. Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. HC Wainwright reissued a “buy” rating and issued a $53.00 price target on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $56.00.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE opened at $39.21 on Friday. The firm has a market cap of $2.99 billion, a P/E ratio of -13.90 and a beta of 1.20. Xenon Pharmaceuticals Inc. has a 1 year low of $35.53 and a 1 year high of $50.99. The firm’s 50 day moving average price is $40.04 and its 200 day moving average price is $40.71.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.82) by $0.01. During the same period last year, the firm posted ($0.73) EPS. As a group, equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current year.

Insider Buying and Selling

In other Xenon Pharmaceuticals news, CFO Sherry Aulin sold 18,709 shares of the stock in a transaction that occurred on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ian Mortimer sold 16,315 shares of the business’s stock in a transaction on Monday, January 27th. The shares were sold at an average price of $40.50, for a total transaction of $660,757.50. Following the sale, the chief executive officer now directly owns 31,302 shares of the company’s stock, valued at $1,267,731. This represents a 34.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 62,383 shares of company stock worth $2,535,891. 5.52% of the stock is owned by company insiders.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.